{"url_path":"/sec/pom/10-k/2026/item-6","section_key":"item-6","section_title":"Item 6 DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1877971/0001213900-26-056576-index.html","accession_number":"0001213900-26-056576","cik":"0001877971","ticker":"POM","issuer_name":"POMDOCTOR Ltd","edgar_url":"https://www.sec.gov/Archives/edgar/data/1877971/0001213900-26-056576-index.html","primary_entity_key":"0001877971","primary_entity_name":"POMDOCTOR Ltd"},"word_count":4785,"has_tables":true,"body_markdown":"ITEM 6.DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES\n\n \n\n6.A. Directors and Senior Management\n\n \n\nThe following table sets\nforth the name, age and position of each of our directors and executive officers as of the date of this annual report.\n\n \n\n**Directors and Executive Officers**\n \n**Age**\n \n**Position/Title**\n\nZhenyang Shi\n \n49\n \nDirector, Chairman, Chief Executive Officer\n\nLi Xu\n \n52\n \nChief Financial Officer\n\nGuoji Luo\n \n41\n \nDirector, Vice President\n\nYuanyuan Jing\n \n46\n \nIndependent Director\n\nWenqing Bao\n \n54\n \nIndependent Director\n\nDaxue Li\n \n55\n \nIndependent Director\n\n \n\n*Zhenyang Shi*is our\nco-founder and chief executive officer, and has served as the chairman of the board of directors since our inception. He obtained his\ncollege degree in clinical medicine from BengBu Medical College in 2000, and he obtained an Executive Master of Business Administration\nin 2017 from China Europe International Business School. With more than a decade of entrepreneurial experience in the healthcare and\nInternet industries, he has received various accolades for his distinctive contribution in the digital health and wellness industry,\nincluding Liwan District Medical and Health Industry Development Consultant in 2016, 2015 – 2016 Pharmaceutical E-Commerce\nInfluential Figure, 2014 – 2015 Pharmaceutical E-Commerce Influential Figure, 2014 Outstanding CEO of China Pharmaceutical\nE-commerce and 2023 Public Welfare Personality Award, the inaugural Clinical Medicine Award in 2023. Mr. Shi’s spouse is Li\nXu, our chief financial officer.\n\n \n\n*Li Xu*is our co-founder\nand has served as our financial manager since our inception. Ms. Xu has served as our chief financial officer since February 2025. She\nobtained her college degree in clinical medicine from BengBu Medical College in 2000 and accumulated a decade of entrepreneurial experience\nin the healthcare and Internet industries before joining Mr. Shi’s effort of co-founding Guangzhou Qilekang Pharmaceutical\nChain Co., Ltd. in 2010. She obtained more than a decade of experience managing various subsidiaries in our Group. She obtained a pharmacist\nlicense in 2015. Ms. Xu’s spouse is Zhenyang Shi, our chairman of the board of directors and chief executive officer.\n\n \n\n*Guoji Luo* has served\nin our Group since 2011 and as our Vice President and Assistant to President since 2019. Mr. Luo has served as our director since\nSeptember 2025. His experience in our Group covers a range of departments, including IT, warehousing and logistics, operations, human\nresources and financing, and he held various positions in our Group including IT department head, deputy manager of warehousing and logistics\ndepartment, E-commerce operation service department head, assistant to the president, deputy manager of Qilekang doctor business development\nand deputy manager of human resources. Before joining our Group, he served in Guangzhou Infoscape Technology Co., Ltd. where he accumulated\nsignificant experience in software product development and product planning and management. He obtained his college degree in information\nnetwork engineering from Guangdong Construction Polytechnic in 2005 and graduated from Sun Yat-sen University in 2011 with a Bachelor’s\ndegree in business administration. He also graduated from China Europe International Business School with a Master of Business Administration\nin 2021.\n\n \n\n*Yuanyuan Jing*has served\nas our independent director since September 2025. Ms. Jing has served as a managing director at Galaxy Capital since 2019, and served\nas a partner of Haichuanghui, a subsidiary of Haier Group Corporation, from 2017 to 2019. She also served as a vice president of the\nhuman resources and administration department at Yibete Information Technology Co., Ltd. from 2013 to 2017. Prior to that, Ms. Jing served\nas a finance manager at Unilever Belgique. Ms. Jing holds an MBA from Hasselt University, a master’s degree in applied economics\nfrom Hasselt University, and a bachelor’s degree in monetary and banking from Shenyang Agricultural University.\n\n* *\n\n*Wenqing Bao*has served\nas our independent director since September 2025. Mr. Bao has served as a general manager at Xing and Hai Trading Co., Ltd. since\n2013. Prior to that, he co-founded Guangzhou Yiji Electric Technology Co., Ltd. Mr. Bao obtained his bachelor’s degree in\nChinese language and literature from Qingdao University in 1996.\n\n \n\n105\n\n \n\n \n\n*Daxue Li*has served\nas our independent director since September 2025. Mr. Li has served as chief executive officer of Beijing Ciyun Digital Technology\nCo., Ltd. since 2015, and served as a senior vice president at JD Group from 2008 to 2015. Mr. Li holds a DBA from Cheung Kong Graduate\nSchool of Business, an EMBA from China Europe International Business School, a master’s degree in automation from Chongqing University,\nand a bachelor’s degree in mathematics from Shandong University.\n\n \n\n6.B. Compensation\n\n \n\nFor the year ended December 31,\n2025, we paid an aggregate of RMB1.4 million (US$0.2 million) in cash to our executive officers and directors, respectively. We have\nnot set aside or accrued any amount to provide pension, retirement or other similar benefits to our directors and executive officers.\nOur PRC subsidiaries and our VIE are required by law to make contributions equal to certain percentages of each employee’s salary\nfor his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund.\n\n \n\nEmployment Agreements and Indemnification\nAgreements\n\n \n\nWe have entered into employment\nagreements with each of our executive officers. Under these agreements, each of our executive officers is employed for a specified time\nperiod. We may terminate employment for cause, at any time, without advance notice or remuneration, for certain acts of the executive\nofficer, such as conviction or plea of guilty to a felony or any crime involving moral turpitude, negligent or dishonest acts to our\ndetriment, or misconduct or a failure to perform agreed duties. We may also terminate an executive officer’s employment without\ncause upon three-month advance written notice. In such case of termination by us, we will provide severance payments to the executive\nofficer as expressly required by applicable law of the jurisdiction where the executive officer is based. The executive officer may resign\nat any time with a three-month advance written notice.\n\n \n\nEach executive officer has\nagreed to hold, both during and after the termination or expiry of his or her employment agreement, in strict confidence and not to use,\nexcept as required in the performance of his or her duties in connection with the employment or pursuant to applicable law, any of our\nconfidential information or trade secrets, any confidential information or trade secrets of our customers or prospective customers, or\nthe confidential or proprietary information of any third party received by us and for which we have confidential obligations. The executive\nofficers have also agreed to disclose in confidence to us all inventions, designs, and trade secrets which they conceive, develop, or\nreduce to practice during the executive officer’s employment with us and to assign all right, title and interest in them to us,\nand assist us in obtaining and enforcing patents, copyrights and other legal rights for these inventions, designs, and trade secrets.\n\n \n\nIn addition, each executive\nofficer has agreed to be bound by non-competition and non-solicitation restrictions during the term of his or her employment and typically\nfor one year following the last date of employment. Specifically, each executive officer has agreed not to (i) approach our suppliers,\nclients, customers or contacts or other persons or entities introduced to the executive officer in his or her capacity as a representative\nof us for the purpose of doing business with such persons or entities that will harm our business relationships with these persons or\nentities; (ii) assume employment with or provide services to any of our competitors, or engage, whether as principal, partner, licensor\nor otherwise, any of our competitors, without our express consent; or (iii) seek directly or indirectly, to solicit the services\nof any of our employees who is employed by us on or after the date of the executive officer’s termination, or in the year preceding\nsuch termination, without our express consent.\n\n \n\nWe have also entered into\nindemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors\nand executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of\ntheir being a director or officer of our company.\n\n \n\n106\n\n \n\n \n\nShare Incentive Plan\n\n** **\n\n**2025 Share Incentive Plan**\n\n** **\n\nIn February 2025, we adopted\nthe 2025 Share Incentive Plan, or the 2025 Plan, effective upon the SEC’s declaration of effectiveness of our registration statement\non Form F-1, for the purpose of granting share-based compensation awards to selected directors, employees and other eligible persons\nto incentivize their performance and align their interests with ours. The maximum aggregate number of Class A ordinary shares which may\nbe issued pursuant to all awards under the 2025 Plan is 3,317,204.\n\n \n\nAs of the date of this annual\nreport, all share awards for an aggregate of 3,317,204 Class A ordinary shares have been granted and have vested pursuant to the 2025\nPlan.\n\n \n\nThe following paragraphs describe\nthe principal terms of the 2025 Plan.\n\n \n\n*Type of awards.*\nThe 2025 Plan permits the awards of options, restricted shares, and restricted share units or other types of awards approved by our\nboard of directors or a committee appointed by our board of directors.\n\n \n\n*Plan administration.* The\n2025 Plan shall be administered by our board of directors or a committee appointed by the board of directors.\n\n \n\n*Award agreement.* Awards\nunder the 2025 Plan are evidenced by an award agreement that set forth the terms, conditions and limitations for each award which may\ninclude the term of an award, the provisions applicable in the event the participant’s employment or service terminates, and our\nauthority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind an award.\n\n \n\n*Eligibility.* We\nmay grant awards to employees, consultants, and directors of our company and our subsidiaries and consolidated affiliated entities.\n\n \n\n*Vesting schedule.*\nIn general, our board of directors or a committee appointed by the board of directors determines the vesting schedule, which is\nspecified in the relevant award agreement.\n\n \n\n*Exercise of\nAwards.* The plan administrator determines the exercise or purchase price, as applicable, the payment methods and the time or\ntimes of exercise, for each award, which are stated in the relevant award agreement. However, the maximum exercisable term is ten\nyears from the date of grant.\n\n \n\n*Transfer\nRestrictions.* Unless otherwise expressly provided by applicable laws and by the award agreement, all awards are non-transferable\nand will not be subject in any manner to sale, transfer, anticipation, alienation, assignment, pledge, encumbrance or charge.\n\n \n\n*Termination and\nAmendment.* Unless terminated earlier, the 2025 Plan has a term of ten years from its date of effectiveness. The administrator\nmay at any time and from time to time terminate, amend, or modify the 2025 Plan. Otherwise no termination, amendment, or\nmodification of the 2025 Plan shall adversely affect in any material way any award previously granted pursuant to the 2025 Plan\nwithout the prior written consent of the participant.\n\n \n\nAs of the date of this annual\nreport, we do not have any outstanding options.\n\n \n\n6.C. Board Practices\n\n \n\nBoard of Directors\n\n \n\nOur board of directors consists\nof five directors. A director is not required to hold any shares in our company by way of qualification. Subject to the Nasdaq Stock\nMarket Rules and disqualification by the chairman of the relevant board meeting, a director may vote with respect to any contract, proposed\ncontract, or arrangement in which he is interested and if he does so his vote shall be counted and he may be counted in the quorum at\nany meeting of our directors at which any such contract or proposed contract or arrangement is considered, provided that (i) such\ndirector has declared the nature of his interest at or prior to its consideration and any vote thereon if he knows his interest then\nexists, or in any other case at the first meeting of the board after he knows he is or has become so interested, either specifically\nor by way of a general notice and (ii) if such contract or arrangement is a transaction with a related party, such transaction has\nbeen approved by the audit committee. The directors may exercise all the powers of the company to borrow money, mortgage or charge its\nundertaking, property, and uncalled capital, and issue debentures or other securities whenever money is borrowed or as security for any\ndebt, liability, or obligation of the company or of any third party. None of our directors has a service contract with us that provides\nfor benefits upon termination of service as a director.\n\n \n\n107\n\n \n\n \n\n**Committees of the Board of Directors**\n\n** **\n\nWe have established three\ncommittees under the board of directors: an audit committee, a compensation committee, and a nominating and corporate governance committee.\nWe have adopted a charter for each of the three committees. Each committee’s members and functions are described below.\n\n \n\n*Audit Committee.*Our audit committee consists of Yuanyuan Jing, Wenqing Bao and Daxue\nLi. Yuanyuan Jing is the chairman of our audit committee. We have determined that Yuanyuan Jing, Wenqing Bao and Daxue Li each satisfies\nthe “independence” requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules and meet the independence standards\nunder Rule 10A-3 under the Exchange Act. We have determined that Yuanyuan Jing qualifies as an “audit committee financial\nexpert.” The audit committee oversees our accounting and financial reporting processes and the audits of the financial statements\nof our company. The audit committee is responsible for, among other things:\n\n \n\n●appointing the\nindependent auditors and pre-approving all auditing and non-auditing services permitted to\nbe performed by the independent auditors;\n\n \n\n●reviewing with\nthe independent auditors any audit problems or difficulties and management’s response;\n\n \n\n●discussing the\nannual audited financial statements with management and the independent auditors;\n\n \n\n●reviewing the adequacy\nand effectiveness of our accounting and internal control policies and procedures and any\nsteps taken to monitor and control major financial risk exposures;\n\n \n\n●establishing procedures\nfor the receipt, retention and treatment of complaints received by us regarding accounting,\ninternal accounting controls or auditing matters;\n\n \n\n●reviewing and approving\nall proposed related party transactions;\n\n \n\n●meeting separately\nand periodically with management and the independent auditors; and\n\n \n\n●monitoring compliance\nwith our code of business conduct and ethics, including reviewing the adequacy and effectiveness\nof our procedures to ensure proper compliance.\n\n \n\n*Compensation\nCommittee.*Our compensation committee consists of Zhenyang Shi, Guoji Luo and Wenqing Bao. Zhenyang Shi is the chairman of our\ncompensation committee. We have determined that Wenqing Bao satisfies the “independence” requirements of\nRule 5605(a)(2) of the Nasdaq Stock Market Rules. The compensation committee assists the board in reviewing and approving\nthe compensation structure, including all forms of compensation, relating to our directors and executive officers. Our chief\nexecutive officer may not be present at any committee meeting during which his compensation is deliberated. The compensation\ncommittee is responsible for, among other things:\n\n \n\n●reviewing and approving,\nor recommending to the board for its approval, the compensation for our chief executive officer\nand other executive officers;\n\n \n\n●reviewing and recommending\nto the board for determination with respect to the compensation of our non-employee directors;\n\n \n\n●reviewing periodically\nand approving any incentive compensation or equity plans, programs or similar arrangements;\nand\n\n \n\n●selecting a compensation\nconsultant, legal counsel or other adviser only after taking into consideration all factors\nrelevant to that person’s independence from management.\n\n \n\n108\n\n \n\n \n\n*Nominating and Corporate\nGovernance Committee. *Our nominating and corporate governance committee consists of Zhenyang Shi, Guoji Luo\nand Daxue Li. Zhenyang Shi is the chairman of our nominating and corporate governance committee. We have determined that Daxue Li satisfies\nthe “independence” requirements of Rule 5605(a)(2) of the Nasdaq Stock Market Rules. The nominating and corporate\ngovernance committee assists the board of directors in selecting individuals qualified to become our directors and in determining the\ncomposition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things:\n\n \n\n●selecting and recommending\nto the board nominees for election by the shareholders or appointment by the board;\n\n \n\n●reviewing annually\nwith the board the current composition of the board with regards to characteristics such\nas independence, knowledge, skills, experience and diversity;\n\n \n\n●overseeing the\nperformance of the board and management and monitoring the functioning of the committees\nof the board; and\n\n \n\n●advising the board\nperiodically with regards to significant developments in the law and practice of corporate\ngovernance as well as our compliance with applicable laws and regulations, and making recommendations\nto the board on all matters of corporate governance and on any remedial action to be taken.\n\n \n\n**Duties of Directors**\n\n \n\nUnder Cayman Islands law,\nour directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly, and a duty to act in what they\nconsider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors\nalso owe to our company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance\nof his duties a greater degree of skill than what may reasonably be expected from a person of his knowledge and experience. However,\nEnglish and Commonwealth courts have moved towards an objective standard with regard to the required skill and care, and these authorities\nare likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure compliance with our\nfourth amended and restated memorandum and articles of association, as amended and restated from time to time, and the class rights vested\nthereunder in the holders of the shares. Our company has the right to seek damages if a duty owed by our directors is breached. In limited\nexceptional circumstances, a shareholder may have the right to seek damages in the company’s name if a duty owed by the directors\nis breached.\n\n \n\nOur board of directors has\nall the powers necessary for managing, and for directing and supervising, our business affairs. The functions and powers of our board\nof directors include, among others:\n\n \n\n●convening shareholders’\nannual general meetings (if required by applicable laws) and reporting its work to shareholders\nat such meetings;\n\n \n\n●declaring dividends\nand distributions;\n\n \n\n●appointing officers\nand determining the term of office of the officers;\n\n \n\n●exercising the\nborrowing powers of our company and mortgaging the property of our company; and\n\n \n\n●approving the transfer\nof shares in our company, including the registration of such shares in our register of members.\n\n \n\n**Terms of Directors and Officers**\n\n \n\nOur directors may be elected\nby an ordinary resolution of our shareholders. Alternatively, our board of directors may, by the affirmative vote of a simple majority\nof the directors present and voting at a board meeting or by a unanimous written resolution appoint any person as a director to fill\na casual vacancy on our board or as an addition to the existing board. Our directors are not automatically subject to a term of office\nand hold office until such time as they are removed from office by an ordinary resolution of our shareholders. In addition, a director\nwill cease to be a director if he (i) becomes bankrupt or makes any arrangement or composition with his creditors; (ii) dies\nor is found to be or becomes of unsound mind; (iii) resigns his office by notice in writing; (iv) without special leave of\nabsence from our board, is absent from meetings of our board for three consecutive meetings and our board resolves that his office be\nvacated; or (v) is removed from office pursuant to any other provision of our articles of association.\n\n \n\nOur officers are appointed\nby and serve at the discretion of the board of directors, and may be removed by our board of directors.\n\n \n\n109\n\n \n\n \n\n6.D. Employees\n\n \n\nAs of December 31, 2025,\nwe had 165 full-time employees, all of whom were based in China, primarily at our headquarters in Guangzhou, China.\n\n \n\nThe following table sets forth\nthe number of our employees by function as of December 31, 2025.\n\n \n\nFunction \nNumber of\n\nEmployees  \nPercentage \n\nSales and Marketing \n 81  \n 49.1%\n\nResearch and Development \n 19  \n 11.5%\n\nGeneral Administration \n 15  \n 9.1%\n\nOthers \n 50  \n 30.3%\n\nTotal \n 165  \n 100.0%\n\n \n\nOur success depends on our\nability to attract, retain, and motivate qualified personnel. As part of our retention strategy, we offer employees competitive salaries,\nperformance-based cash bonuses, regular awards, and long-term incentives.\n\n \n\nWe primarily recruit our employees\nthrough recruitment agencies, on-campus job fairs, internal referrals, and online channels. In addition to on-the-job training, we have\nadopted a training system, pursuant to which management, technology, regulatory, and other trainings are regularly provided to our employees\nby internally sourced speakers or externally hired consultants. Our employees may also attend external trainings upon their supervisors’\napprovals.\n\n \n\nAs required by PRC laws and\nregulations in respect of our PRC employment, we participate in housing provident fund and various employee social insurance plans that\nare organized by applicable competent authorities, including housing, pension, medical, work-related injury, maternity, and unemployment\ninsurance, under which we make contributions at specified percentages of the salaries of our employees. For our compliance status with\nthe housing provident fund and various employee social insurance plans, see “Item 3. Key Information—3.D. Risk Factors—Risks\nRelated to Our Business and Industry—We are not in full compliance with PRC labor laws and regulations, including but not limited\nto labor, social insurance and housing provident fund.” Bonuses are generally discretionary and based in part on employee performance\nand in part on the overall performance of our business.\n\n \n\nWe enter into standard confidentiality\nand employment agreements with our employees. The contracts with our key personnel typically include a standard non-compete covenant\nthat prohibits the employee from competing with us, directly or indirectly, during his or her employment and for two years after\nthe termination of his or her employment, provided that we pay a certain amount of compensation during the restriction period.\n\n \n\n6.E. Share Ownership\n\n \n\nThe following table sets forth information concerning\nthe beneficial ownership of our ordinary shares as of March 31, 2026 by:\n\n \n\n●each of our directors\nand executive officers; and\n\n \n\n●each person known\nto us to beneficially own more than 5% of our ordinary shares.\n\n \n\nThe calculations in the table\nbelow are based on 22,365,760 ordinary shares issued and outstanding as of March 31, 2026, including 20,323,718 Class A ordinary\nshares and 2,042,042 Class B ordinary shares. Each holder of Class B ordinary shares is entitled to twenty votes per share and\neach holder of our Class A ordinary shares is entitled to one vote per share on all matters submitted to them for a vote.\n\n \n\nBeneficial ownership is determined\nin accordance with the rules and regulations of the SEC. In computing the number of shares beneficially owned by a person and the\npercentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including\nthrough the exercise of any option, warrant or other right or the conversion of any other security. These shares, however, are not included\nin the computation of the percentage ownership of any other person.\n\n \n\n110\n\n \n\n \n\n  \nOrdinary Shares Beneficially Owned \n\n  \nClass A Ordinary Shares  \nClass B Ordinary Shares  \nTotal Ordinary Shares on an As Converted Basis*  \n% of Beneficial Ownership*  \nAggregate Voting Power ** \n\nDirectors and Executive Officers†: \n   \n   \n   \n   \n  \n\nZhenyang Shi (1) \n 3,676,842  \n 2,042,042  \n 5,718,884  \n 25.6% \n 72.8%\n\nLi Xu (2) \n -  \n 800,000  \n 800,000  \n 3.6% \n - \n\nGuoji Luo \n -  \n -  \n -  \n -  \n - \n\nYuanyuan Jing \n -  \n -  \n -  \n -  \n - \n\nWenqing Bao \n -  \n -  \n -  \n -  \n - \n\nDaxue Li \n -  \n -  \n -  \n -  \n - \n\n**All Directors and Executive Officers as a Group(3)** \n 3,676,842  \n 2,042,042  \n 5,718,884  \n 25.6% \n 72.8%\n\nPrincipal Shareholders: \n    \n    \n    \n    \n   \n\nHEALTHYSEVEN LIMITED (1) \n 2,268,156  \n 1,242,042  \n 3,510,198  \n 15.7% \n 44.3%\n\nDan Hong (H.K.) Technology Limited(4) \n 2,957,613  \n -  \n 2,957,613  \n 13.2% \n 4.8%\n\nNova Compass Investment Limited(5) \n 1,958,119  \n -  \n 1,958,119  \n 8.8% \n 3.2%\n\nBeijing Gaotejia Technology Partnership (Limited Partnership)(6) \n 1,358,995  \n -  \n 1,358,995  \n 6.1% \n 2.2%\n\n \n\n \n\nNotes:\n\n \n\n†Except as otherwise indicated below, the business address of our\ndirectors and executive officers is Yongxu Industrial Park, No.19-23, Hejing Road, Dongsha Street,\nLiwan District, Guangzhou 510000, People’s Republic of China.\n\n \n\n*\nFor each person and group included in this column, percentage ownership\nis calculated by dividing the number of shares beneficially owned by such person or group by the sum of the total number of shares outstanding\nand the number of shares such person or group has the right to acquire upon exercise of option, warrant or other right within 60 days\nafter March 31, 2026.\n\n \n\n**\nFor each person and group included in this column, percentage of voting\npower is calculated by dividing the voting power beneficially owned by such person or group by the voting power of all of our ordinary\nshares as a single class. Each Class A ordinary share is entitled to one vote and each Class B ordinary share is entitled to 20 votes.\nEach Class B ordinary share is convertible into one Class A ordinary share at any time by the holder thereof. Class A ordinary shares\nare not convertible into Class B ordinary shares under any circumstances.\n\n \n\n(1)Represents (i) 2,268,156 Class\nA ordinary shares held by HEALTHYSEVEN LIMITED, a company incorporated in British Virgin\nIslands, (ii) 800,000 Class A ordinary shares held by Guangzhou Jinpin Management Consulting\nPartnership (Limited Partnership), a PRC limited partnership, (iii) 500,000 Class A ordinary\nshares held by Guangzhou Jinshang Management Consulting Partnership (Limited Partnership),\na PRC limited partnership, (iv) 108,686 Class A ordinary shares held by Guangzhou Jinyue\nManagement Consulting Partnership (Limited Partnership), a PRC limited partnership, (v) 1,242,042\nClass B ordinary shares held by HEALTHYSEVEN LIMITED, and (vi) 800,000 Class B ordinary shares\nheld by HEALTHYTEN LIMITED, which has granted an irrevocable voting proxy for all shares\nbeneficially owned by it to Zhenyang Shi.\n\n \n\n111\n\n \n\n \n\nHEALTHYSEVEN LIMITED is wholly owned\nby Zhenyang Shi. The registered address of HEALTHYSEVEN LIMITED is OMC Chambers, Wickhams Cay 1, Road Town, Tortola, British Virgin Islands.\n\n \n\nThe general partner of each of Guangzhou\nJinpin Management Consulting Partnership (Limited Partnership), Guangzhou Jinshang Management Consulting Partnership (Limited Partnership)\nand Guangzhou Jinyue Management Consulting Partnership (Limited Partnership) is Guangzhou Jinji Management Consulting Co., Ltd. Zhenyang\nShi is the controlling shareholder of Guangzhou Jinji Management Consulting Co., Ltd. The registered address of each of Guangzhou Jinpin\nManagement Consulting Partnership (Limited Partnership), Guangzhou Jinshang Management Consulting Partnership (Limited Partnership) and\nGuangzhou Jinyue Management Consulting Partnership (Limited Partnership) is No. 106 Fengze East Road, Nansha District, Guangzhou, People’s\nRepublic of China.\n\n \n\n(2)Represents 800,000 Class B ordinary\nshares held by HEALTHYTEN LIMITED. HEALTHYTEN LIMITED is a company incorporated in British\nVirgin Islands and wholly owned by Li Xu. Li Xu, spouse of Zhenyang Shi, has granted an irrevocable\nvoting proxy to Zhenyang Shi in connection with Class B ordinary shares held by HEALTHYTEN\nLIMITED. The registered address of HEALTHYTEN LIMITED is OMC Chambers, Wickhams Cay 1, Road\nTown, Tortola, British Virgin Islands.\n\n \n\n(3)In order to avoid double counting,\nthe total number of ordinary shares owned by all directors and executive officers as a group\nonly reflects ordinary shares that are owned directly or indirectly by all directors and\nexecutive officers without taking into account the related voting proxy granted to Zhenyang\nShi. See Note (1) for a detailed description of the related voting proxy arrangement.\n\n \n\n(4)Represents 2,957,613 Class A ordinary\nshares held by Dan Hong (H.K.) Technology Limited, a Hong Kong limited company. The registered\naddress of Dan Hong (H.K.) Technology Limited is Unit 803, 8/F., Shanghai Industrial Investment\nBuilding, 48-62 Hennessy Road, Wanchai, Hong Kong. Dan Hong (H.K.) Technology Limited\nis wholly owned by Shandong Buchang Pharmaceutical Co., Ltd. Shandong Buchang Pharmaceutical\nCo., Ltd. is controlled by Dade Holdings Limited, which is wholly owned by Tao Zhao.\n\n \n\n(5)Represents 1,958,119 Class A ordinary\nshares held by Nova Compass Investment Limited, a company incorporated in the British Virgin\nIslands. The registered address of Nova Compass Investment Limited is OMC Chambers, Wickhams\nCay 1, Road Town, Tortola, British Virgin Islands. Nova Compass Investment Limited is controlled\nby Focus Media Information Technology Co., Ltd. (a company listed on the Shenzhen Stock Exchange,\nstock code: 002027), which is controlled by Nanchun Jiang.\n\n \n\n(6)Represents 1,358,995 Class A ordinary\nshares directly held by Beijing Gaotejia Technology Partnership (Limited Partnership), a\nPRC limited partnership. The general partner of Beijing Gaotejia Technology Partnership (Limited\nPartnership) is Huipeng Mao. The registered address of Beijing Gaotejia Technology Partnership\n(Limited Partnership) is 25221, 2nd Floor, Building A1, No.1 Huangchang West\nRoad, DougeZhuang, Chaoyang District, Beijing, China.\n\n \n\nTo our best knowledge, as\nof March 31, 2026, 3,458,334 of our outstanding Class A ordinary shares were held by one record holder in the United States, which\nis the depositary of our ADS program. The number of beneficial owners of the ADSs in the United States is likely to be much larger than\nthe number of record holders of our Class A ordinary shares in the United States. None of our shareholders has informed us that\nit is affiliated with a member of Financial Industry Regulatory Authority, or FINRA.\n\n \n\nWe are not aware of any arrangement\nthat may, at a subsequent date, result in a change of control of our company."}